A National Cancer Institute of Canada Clinical Trials Group Study – IND.135: Phase I/II study of irinotecan (camptosar), oxaliplatin and raltitrexed (tomudex) (COT) in patients with advanced colorectal cancerJean A. Maroun, G. Chiritescu, Derek J. Jonker et al.|European Journal of Cancer|2005Cited by 9
A Phase I Study of Irinotecan, Capecitabine (Xeloda), and Oxaliplatin in Patients With Advanced Colorectal CancerJean A. Maroun, G. Chiritescu, C. Cripps et al.|Clinical Colorectal Cancer|2017Cited by 9
Encouraging results from a phase I study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with metastatic colorectal cancer (MCRC)Jean A. Maroun, G. Chiritescu, Derek J. Jonker et al.|Journal of Clinical Oncology|2007Cited by 4
A phase I/II study of capecitabine (X), irinotecan (I) and oxaliplatin (O) as first-line therapy in patients (pts) with advanced or metastatic colorectal cancer (MCRC)Jean A. Maroun, G. Chiritescu, Derek J. Jonker et al.|Journal of Clinical Oncology|2006Cited by 2
242 Phase I study of irinotecan (I), raltitrexed (R), and 5-fluorouracil (5FU) in the treatment of metastatic colorectal cancer (MCRC) refractory to thymidylate synthase inhibitors (TSI)Rakesh Goel, Leslie Douglas, C. Cripps et al.|European Journal of Cancer Supplements|2003Cited by 0